Dyslipidemia in Chronic Kidney Disease Patients at Dr. Soetomo Hospital Surabaya
Dislipidemia pada Pasien Penyakit Ginjal Kronis di RSUD Dr. Soetomo Surabaya
Abstract
Epidemiological studies report that patients with chronic kidney disease (CKD) have a higher risk of mortality from cardiovascular disease than the general population. Previous studies have shown that dyslipidemia is thought to play a role in the development of atherosclerosis in patients with CKD. Dyslipidemia is known to be common in CKD patient population, but shows a diverse patterns in various CKD patient populations. This study aimed to analyze the lipid profile and lipid ratio in CKD patients at Dr. Soetomo Hospital Surabaya for the period 2016-2017. This cross-sectional study was conducted through retrospective observation of the medical records of CKD patient at the Kidney-Hypertension Polyclinic of Dr. Soetomo Hospital Surabaya in the 2016-2017 period. A total of 68 research subjects were analyed in this study. Most of the study subjects were male (68%) and the median age was 54 years. Almost 70% of the study subjects had CKD stage 5. Increased levels of total cholesterol and triglyceride were found in 37% of the study subjects. Meanwhile, a decreae in HDL-cholesterol levels and an increase in LDL-cholesterol and non-HDL-cholesterol levels were found in 60% of the study subjects. The mean value of total cholesterol, LDL-cholesterol, and non-HDL-cholesterol levels in the female group was siginificantly higher based on statistical calculations (p0.05). Most of the study subjects were predicted to be at risks for developing cardiovascular disease based on the calculation of several lipid ratios. The incidence of dyslipidemia in population is known to be higher than in the general population. Decreased HDL-cholesterol, increased LDL-cholesterol, and non-HDL-cholesterol are the most common forms of dyslipidemia in population studies.
Abstrak
Studi epidemiologi melaporkan bahwa pasien penyakit ginjal kronis memiliki risiko mortalitas akibat penyakit kardiovaskular yang lebih tinggi dibandingkan populasi umum. Studi sebelumnya menunjukkan bahwa dislipidemia diduga turut berperan terhadap terjadinya atherosklerosis pada pasien penyakit ginjal kronis. Dislipidemia diketahui umum ditemukan pada populasi pasien penyakit ginjal kronis namun menunjukkan pola yang bervariasi pada berbagai populasi pasien penyakit ginjal kronis. Studi ini bertujuan untuk menganalisis profil lipid dan rasio lipid pada pasien penyakit ginjal kronis di RSUD Dr. Soetomo Surabaya periode 2016-2017. Studi cross-sectional ini dilakukan melalui pengamatan retrospektif terhadap catatan rekam medis pasien penyakit ginjal kronis di Poliklinik Ginjal-Hipertensi RSUD Dr. Soetomo Surabaya pada periode 2016-2017. Sebanyak 68 subjek penelitian dianalisis dalam penelitian ini. Sebagian besar subjek penelitian berjenis kelamin laki-laki (68%) dan nilai median usia pada subjek penelitian mencapai 54 tahun. Sebagian besar subjek penelitian memiliki penyakit ginjal kronis stadium 5 (70%). Peningkatan kadar kolesterol total dan trigliserida ditemukan pada sekitar 37% subjek penelitian. Sedangkan penurunan kadar HDL-kolesterol dan peningkatan kadar LDL-kolesterol serta non HDL-kolesterol ditemukan pada sekitar 60% subjek penelitian. Nilai rerata kadar kolesterol total, LDL-kolesterol, dan non HDL-kolesterol pada kelompok berjenis kelamin perempuan secara signifikan lebih tinggi berdasarkan perhitungan statistika (p0.05). Sebagian besar subjek penelitian diprediksi memiliki risiko untuk mengalami penyakit kardiovaskular berdasarkan perhitungan beberapa rasio lipid. Insiden dislipidemia pada studi populasi diketahui lebih tinggi dibandingkan populasi umum. Penurunan HDL-kolesterol, peningkatan LDL-kolesterol, dan non HDL-kolesterol merupakan bentuk dislipidemia yang paling umum ditemukan pada studi populasi.
References
Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-272.
World Health Organization (WHO). Global Report on Diabetes 2016; Geneva, Switzerland:WHO; 2016.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441-50.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-52.
Drueke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723-35.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial, Lancet. 2011;377(9784):2181-192.
Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290(2):262-72.
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3):259- 305.
Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10: 35-45.
Millan J, Pinto X, Munoz A, Zuniga M, Rubies- Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757-65.
Badan Penelitian dan Pengembangan Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar 2013. 2013:1-306.
Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013;6(1):14- 17.
National Cholesterol Education Program (NCEP) Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-497.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient- centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9(2):129-69.
Castelli WP, Abbott RD, Mcnamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67(4):730-34.
Castelli WP, Garrison RJ, Wilson PWF, Abbott R, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol level: The Framingham Study. JAMA. 1986;256(20):2835- 838.
Mclaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals risk of cardiovascular disease?. Am J Cardiol. 2005;96(3):399-404.
Dobiasova M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006;52(1):64-71.
Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2015;55(3 0 2):23-33.
Takahashi S, Okada K, Yanai M. The Kidney Early Evaluation Program (KEEP) of Japan: Results from the initial screening period. Kidney Int Suppl. 2010;116:17-23.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2015;365(9455):217-23.
Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-664.
Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419-28.
Sandberg K. Mechanisms underlying sex differences in progressive renal disease. Gend Med. 2008;5(1):10-23.
Doublier S, Lupia E, Catanuto P, Periera-Simon S, Xia X, Korach K, et al. Testosterone and 17-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int. 2011; 79(4):404-13.
Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003- 2006. J Clin Lipidol. 2012;6(4): 325-30.
Holzmann MJ, Jungner I, Walldius G, Ivert T, Nordgvist T, Ostergen J, et al. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Ann Med. 2010;44(3):262-70.
Usui T, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, et al. Serum non-high-density lipoprotein cholesterol and risk of cardiovascular disease in Community Dwellers with chronic kidney disease: the Hisayama Study. J Atheroscler Thromb. 2017;24(7):706-15.
Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(5):1112-120.
Lamprea-Montealegre JA, SharrettAR, Matsushita K, Selvin E, Szklo M, Astor BC. Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: The ARIC Study. Atherosclerosis. 2014;234(1):42-6.
Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566-71.
Phan BAP, Toth PP. Dyslipidemia in women: etiology and management. Int J Women Health. 2014;6:185-94.
Cífkova R, Krajčoviechová A. Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep. 2015;17(7):609.
